BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23817177)

  • 1. RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.
    Koh CP; Wang CQ; Ng CE; Ito Y; Araki M; Tergaonkar V; Huang G; Osato M
    Leukemia; 2013 Sep; 27(9):1793-802. PubMed ID: 23817177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Core binding factor genes and human leukemia.
    Hart SM; Foroni L
    Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
    Huang G; Zhao X; Wang L; Elf S; Xu H; Zhao X; Sashida G; Zhang Y; Liu Y; Lee J; Menendez S; Yang Y; Yan X; Zhang P; Tenen DG; Osato M; Hsieh JJ; Nimer SD
    Blood; 2011 Dec; 118(25):6544-52. PubMed ID: 22012064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disordered epigenetic regulation in MLL-related leukemia.
    Zhang Y; Chen A; Yan XM; Huang G
    Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic mechanism of RUNX1 in pathogenesis of leukemia].
    Zhang H; Zheng HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):525-30. PubMed ID: 20416203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
    Engel ME; Hiebert SW
    Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epigenetic programs in MLL-rearranged leukemias.
    Bernt KM; Armstrong SA
    Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
    Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
    Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for RUNX1 in hematopoiesis and myeloid leukemia.
    Ichikawa M; Yoshimi A; Nakagawa M; Nishimoto N; Watanabe-Okochi N; Kurokawa M
    Int J Hematol; 2013 Jun; 97(6):726-34. PubMed ID: 23613270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When epigenetics kills: MLL fusion proteins in leukemia.
    Slany RK
    Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.
    Wilkinson AC; Ballabio E; Geng H; North P; Tapia M; Kerry J; Biswas D; Roeder RG; Allis CD; Melnick A; de Bruijn MF; Milne TA
    Cell Rep; 2013 Jan; 3(1):116-27. PubMed ID: 23352661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transcription factor RUNX1].
    Markova EN; Petrova NV; Razin SV; Kantidze OL
    Mol Biol (Mosk); 2012; 46(6):846-59. PubMed ID: 23350231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 5' untranslated region containing the IRES element in the Runx1 gene is required for angiogenesis, hematopoiesis and leukemogenesis in a knock-in mouse model.
    Nagamachi A; Htun PW; Ma F; Miyazaki K; Yamasaki N; Kanno M; Inaba T; Honda Z; Okuda T; Oda H; Tsuji K; Honda H
    Dev Biol; 2010 Sep; 345(2):226-36. PubMed ID: 20647008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies.
    Wang H; Li W; Guo R; Sun J; Cui J; Wang G; Hoffman AR; Hu JF
    Int J Cancer; 2014 Dec; 135(12):2783-94. PubMed ID: 24752773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLCA2, a novel RUNX1 partner gene in a therapy-related leukemia with t(1;21)(p22;q22).
    Giguère A; Hébert J
    Cancer Genet Cytogenet; 2010 Oct; 202(2):94-100. PubMed ID: 20875871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1.
    Oakford PC; James SR; Qadi A; West AC; Ray SN; Bert AG; Cockerill PN; Holloway AF
    Leuk Res; 2010 Sep; 34(9):1203-13. PubMed ID: 20439113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1alpha.
    Peng ZG; Zhou MY; Huang Y; Qiu JH; Wang LS; Liao SH; Dong S; Chen GQ
    Oncogene; 2008 Jan; 27(6):839-47. PubMed ID: 17684492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.